What is the pipeline for future medications for obesity?

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatme...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of obesity (2005) Vol. 49; no. 3; p. 433
Main Authors:	Melson, Eka, Ashraf, Uzma, Papamargaritis, Dimitris, Davies, Melanie J
Format:	Journal Article
Language:	English
Published:	England 01.03.2025
Subjects:	Anti-Obesity Agents - therapeutic use Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor Agonists Glucagon-Like Peptides - therapeutic use Humans Obesity - drug therapy
ISSN:	1476-5497, 1476-5497
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.
AbstractList	Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring. Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15-17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.
Author	Davies, Melanie J Ashraf, Uzma Melson, Eka Papamargaritis, Dimitris
Author_xml	– sequence: 1 givenname: Eka orcidid: 0000-0003-0685-4819 surname: Melson fullname: Melson, Eka organization: Diabetes Research Centre, University of Leicester College of Life Sciences, Leicester, UK – sequence: 2 givenname: Uzma surname: Ashraf fullname: Ashraf, Uzma organization: Diabetes Research Centre, University of Leicester College of Life Sciences, Leicester, UK – sequence: 3 givenname: Dimitris orcidid: 0000-0001-5044-1515 surname: Papamargaritis fullname: Papamargaritis, Dimitris email: dp421@leicester.ac.uk, dp421@leicester.ac.uk, dp421@leicester.ac.uk organization: Department of Diabetes and Endocrinology, Kettering General Hospital NHS Foundation Trust, Kettering, NN16 8UZ, UK. dp421@leicester.ac.uk – sequence: 4 givenname: Melanie J orcidid: 0000-0002-9987-9371 surname: Davies fullname: Davies, Melanie J organization: Leicester Diabetes Centre, Leicester General Hospital, Leicester, LE5 4PW, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38302593$$D View this record in MEDLINE/PubMed
BookMark	eNpNj01LxDAYhIOsuB_6BzxIj16ibz6apCeRxS9Y8KJ4LEn6ho1029qkh_33LrqCpxmGh2FmSWZd3yEhlwxuGAhzmyQTSlHgkgKTWtD9CVkcjKKlrPTsn5-TZUqfAFCWwM_IXBgBvKzEgpiPrc1FTEXeYjHEAdvYYRH6sQhTnkYsdthEb3Psu_QT9w5TzPu7c3IabJvw4qgr8v748LZ-ppvXp5f1_YZ6yXWmzJZGSKVDUFgK4ZwJ2hnRGKykFFw7yRRI57Q3VoOyTfAOrAg-BOMb4HxFrn97h7H_mjDleheTx7a1HfZTqnnFKybASHlAr47o5A6z62GMOzvu67-3_Bsdn1i0
CitedBy_id	crossref_primary_10_3389_fphar_2025_1543166 crossref_primary_10_1080_14656566_2024_2356254 crossref_primary_10_3390_scipharm93020026 crossref_primary_10_1007_s00421_025_05852_9 crossref_primary_10_1007_s44371_025_00266_0 crossref_primary_10_2169_internalmedicine_5950_25 crossref_primary_10_1016_j_taap_2024_117125 crossref_primary_10_1007_s12170_025_00761_0 crossref_primary_10_3390_medicina61040678 crossref_primary_10_3390_ph17040478 crossref_primary_10_3390_cells13100870 crossref_primary_10_56095_eaj_v4i1_89 crossref_primary_10_2147_CPAA_S497904 crossref_primary_10_1080_08998280_2025_2480512 crossref_primary_10_1016_S2213_8587_25_00134_2 crossref_primary_10_1038_s44324_024_00032_3 crossref_primary_10_4093_dmj_2025_0106 crossref_primary_10_1007_s12170_024_00740_x crossref_primary_10_1016_j_medj_2025_100805 crossref_primary_10_1016_j_beem_2025_102018 crossref_primary_10_1016_j_rmclc_2025_08_010 crossref_primary_10_1186_s12933_024_02539_x crossref_primary_10_1007_s10865_025_00583_w crossref_primary_10_5937_arhfarm74_50566 crossref_primary_10_3390_biom15081173 crossref_primary_10_1080_13697137_2025_2455177 crossref_primary_10_1007_s12170_025_00770_z crossref_primary_10_1093_ckj_sfaf035 crossref_primary_10_15420_cfr_2025_10 crossref_primary_10_1038_s41392_024_01931_z crossref_primary_10_1111_dom_15869 crossref_primary_10_12968_hmed_2025_0127 crossref_primary_10_1016_j_eclinm_2025_103363 crossref_primary_10_1097_MCO_0000000000001130 crossref_primary_10_1056_NEJMoa2511774 crossref_primary_10_1093_ckj_sfae296 crossref_primary_10_1038_s41467_024_51005_5 crossref_primary_10_1161_JAHA_125_043137 crossref_primary_10_1016_j_medcli_2025_106951 crossref_primary_10_4093_dmj_2025_0047 crossref_primary_10_1016_j_ejphar_2025_177850 crossref_primary_10_1016_j_medcli_2025_107122 crossref_primary_10_7326_ANNALS_24_01590 crossref_primary_10_1186_s42826_024_00233_3 crossref_primary_10_1016_j_bcp_2024_116710 crossref_primary_10_1111_dom_16167 crossref_primary_10_1001_jama_2024_10816 crossref_primary_10_1016_j_tem_2025_06_004 crossref_primary_10_5937_arhfarm74_50625 crossref_primary_10_1080_08998280_2025_2469990 crossref_primary_10_4103_ijem_ijem_45_24 crossref_primary_10_4093_dmj_2025_0561 crossref_primary_10_1016_j_jacc_2025_07_059 crossref_primary_10_1007_s40200_024_01512_5 crossref_primary_10_1001_jama_2024_6586 crossref_primary_10_1016_j_jand_2024_10_023 crossref_primary_10_3310_nihropenres_13784_1 crossref_primary_10_1111_bph_70003 crossref_primary_10_1016_j_mce_2025_112627 crossref_primary_10_7759_cureus_71569 crossref_primary_10_4330_wjc_v17_i8_107991 crossref_primary_10_3390_ijms25158202 crossref_primary_10_1038_s41366_025_01866_7 crossref_primary_10_3390_ph18050614 crossref_primary_10_1038_s41574_025_01151_7 crossref_primary_10_1038_s41371_024_00933_2 crossref_primary_10_1177_08901171251335507c crossref_primary_10_3390_biomedicines12061320 crossref_primary_10_1002_ncp_11279 crossref_primary_10_1038_s42255_024_01113_9 crossref_primary_10_1177_08901171251335507d crossref_primary_10_1007_s40266_024_01150_9 crossref_primary_10_3390_ijms26167744 crossref_primary_10_1016_j_obpill_2025_100205 crossref_primary_10_21215_kjfp_2025_15_1_2 crossref_primary_10_1038_s41574_025_01125_9 crossref_primary_10_1089_dtom_2025_0015 crossref_primary_10_1016_j_mayocp_2024_10_003 crossref_primary_10_3390_cancers16051028 crossref_primary_10_1038_s42255_025_01324_8 crossref_primary_10_3390_biomedicines13020368 crossref_primary_10_1080_17425247_2025_2554718 crossref_primary_10_1152_ajpendo_00156_2024 crossref_primary_10_1186_s41043_025_00953_9 crossref_primary_10_1016_j_cjca_2025_03_037 crossref_primary_10_1080_20415990_2024_2365614 crossref_primary_10_1080_14656566_2024_2436595 crossref_primary_10_1007_s13300_025_01733_8 crossref_primary_10_1007_s11096_024_01779_x crossref_primary_10_1007_s12325_025_03352_y crossref_primary_10_1016_j_tem_2024_04_021 crossref_primary_10_1177_08901171251335507 crossref_primary_10_14341_omet13184 crossref_primary_10_1007_s40273_025_01520_0 crossref_primary_10_1007_s00125_025_06413_7 crossref_primary_10_1007_s11154_025_09967_4 crossref_primary_10_1016_j_ajpc_2025_101281 crossref_primary_10_1097_GME_0000000000002595 crossref_primary_10_3390_pharmaceutics16101310 crossref_primary_10_1016_j_metabol_2024_156057 crossref_primary_10_1186_s10194_025_02071_7 crossref_primary_10_1055_a_2606_7020 crossref_primary_10_1007_s40619_025_01687_w crossref_primary_10_1038_s41574_024_01006_7 crossref_primary_10_3390_medicines12030019 crossref_primary_10_1007_s40005_025_00752_8 crossref_primary_10_3390_ijms25147954 crossref_primary_10_1136_bmj_q2636 crossref_primary_10_2337_dsi24_0004 crossref_primary_10_1038_s41366_025_01734_4 crossref_primary_10_1038_s41575_024_00977_2 crossref_primary_10_1093_sleep_zsaf004 crossref_primary_10_1080_17476348_2025_2513516 crossref_primary_10_3389_fendo_2025_1630199 crossref_primary_10_1111_apt_70196
ContentType	Journal Article
Copyright	2024. The Author(s).
Copyright_xml	– notice: 2024. The Author(s).
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1038/s41366-024-01473-y
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Diet & Clinical Nutrition Recreation & Sports
EISSN	1476-5497
ExternalDocumentID	38302593
Genre	Journal Article Review
GroupedDBID	--- -Q- ..I .GJ .L3 .XZ 0R~ 1CY 29J 2FS 2WC 36B 39C 4.4 406 53G 5GY 5RE 70F 7X2 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 A8Z AACDK AAHBH AANZL AASML AATNV AAWTL AAYZH ABAKF ABAWZ ABBRH ABCQX ABDBE ABDBF ABFSG ABIVO ABJNI ABLJU ABOCM ABRTQ ABUWG ABZZP ACAOD ACGFS ACKTT ACPRK ACRQY ACSTC ACUHS ACZOJ ADBBV ADHUB ADXHL AEFQL AEJRE AEMSY AENEX AEUYN AEVLU AEXYK AEZWR AFBBN AFDZB AFFNX AFHIU AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AI. AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF APEBS ATCPS ATHPR AXYYD AYFIA AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DIK DNIVK DPUIP DU5 DWQXO E3Z EAD EAP EBC EBD EBLON EBS ECM EE. EIF EIOEI EJD EMB EMK EMOBN EPL ESX F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GNUQQ HCIFZ HMCUK HZ~ IAO IHR IHW INH INR IPY ITC IWAJR JSO JZLTJ KQ8 L7B M0K M1P M2M M7P MVM NPM NQJWS O9- OK1 OVD P2P P6G PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PSYQQ Q2X RNS RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UKHRP VH1 WH7 ZGI ZXP ~8M ~KM 7X8
ID	FETCH-LOGICAL-c427t-1a583467ff6e533bb8f7b83d8e944327b41604bb7c8a706adfcb0a3fcff8cd022
IEDL.DBID	7X8
ISICitedReferencesCount	181
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001155820500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1476-5497
IngestDate	Sun Nov 09 10:34:46 EST 2025 Mon Jul 21 05:51:22 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Language	English
License	2024. The Author(s).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c427t-1a583467ff6e533bb8f7b83d8e944327b41604bb7c8a706adfcb0a3fcff8cd022
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ORCID	0000-0001-5044-1515 0000-0003-0685-4819 0000-0002-9987-9371
OpenAccessLink	https://www.nature.com/articles/s41366-024-01473-y.pdf
PMID	38302593
PQID	2929130844
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2929130844 pubmed_primary_38302593
PublicationCentury	2000
PublicationDate	2025-03-01
PublicationDateYYYYMMDD	2025-03-01
PublicationDate_xml	– month: 03 year: 2025 text: 2025-03-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	International journal of obesity (2005)
PublicationTitleAlternate	Int J Obes (Lond)
PublicationYear	2025
SSID	ssj0005502
Score	2.7239995
SecondaryResourceType	review_article
Snippet	Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	433
SubjectTerms	Anti-Obesity Agents - therapeutic use Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor Agonists Glucagon-Like Peptides - therapeutic use Humans Obesity - drug therapy
Title	What is the pipeline for future medications for obesity?
URI	https://www.ncbi.nlm.nih.gov/pubmed/38302593 https://www.proquest.com/docview/2929130844
Volume	49
WOSCitedRecordID	wos001155820500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1LSwMxEMcHtSJefNRXfRFBvIVuN9lNeiqiFg-29KDSW8kTCrKtbhX89k6yW3oSBC97WDawZCeT385M_gNwrZR2IuWOspznlHelpooxRhPrpFS5yXhU-3x9EsOhHI-7ozrgVtZllUufGB21nZkQI2-nuI-jv5Wc9-bvNHSNCtnVuoXGOjQYokwo6RLjlVo40nfMdnKRU_wPEvWhmYTJdonOOw_lt6EGgwtGv39HzLjV9Hf_-5J7sFNDJrmtrGIf1lzRhNb91C3IDamVQN_IcCnE34StQZ1ib0JzBZL4cGyCXh6ADBLfZFoS5EUyn87DKXZHEHhJJUpCYo6-iv7F27Oq4UDvEF76D893j7RuukANT8WCdlQmGXpP73OHKKi19EJLZqXrcs5SoZHgEq61MFKJJFfWG50o5o330lgkgiPYKGaFOwHCfMdyGxTAmEVu8BLZUAtulMOR1mYtuFrO4gSNOmQqVOFmn-VkNY8tOK4-xWReqW9MWFAsy7rs9A-jz2A7Df16Y83YOTQ8Lml3AZvmazEtPy6jteB1OBr8AEFbx9k
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=What+is+the+pipeline+for+future+medications+for+obesity%3F&rft.jtitle=International+journal+of+obesity+%282005%29&rft.au=Melson%2C+Eka&rft.au=Ashraf%2C+Uzma&rft.au=Papamargaritis%2C+Dimitris&rft.au=Davies%2C+Melanie+J&rft.date=2025-03-01&rft.eissn=1476-5497&rft.volume=49&rft.issue=3&rft.spage=433&rft_id=info:doi/10.1038%2Fs41366-024-01473-y&rft_id=info%3Apmid%2F38302593&rft_id=info%3Apmid%2F38302593&rft.externalDocID=38302593
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-5497&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-5497&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-5497&client=summon